CN1151525A - Cancer uroscopy reagent and determining standard colour plate - Google Patents
Cancer uroscopy reagent and determining standard colour plate Download PDFInfo
- Publication number
- CN1151525A CN1151525A CN 96105436 CN96105436A CN1151525A CN 1151525 A CN1151525 A CN 1151525A CN 96105436 CN96105436 CN 96105436 CN 96105436 A CN96105436 A CN 96105436A CN 1151525 A CN1151525 A CN 1151525A
- Authority
- CN
- China
- Prior art keywords
- cancer
- reagent
- colour
- wrine
- standard colour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 29
- 201000011510 cancer Diseases 0.000 title claims abstract description 25
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 22
- 238000009603 uroscopy Methods 0.000 title 1
- 210000002700 urine Anatomy 0.000 claims abstract description 17
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 230000002378 acidificating effect Effects 0.000 claims abstract 2
- 239000007864 aqueous solution Substances 0.000 claims abstract 2
- 238000012216 screening Methods 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims 2
- 238000012360 testing method Methods 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 6
- 239000011669 selenium Substances 0.000 description 5
- 238000002562 urinalysis Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 239000012030 Millon's reagent Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- LUBRVTSBOGIRCS-UHFFFAOYSA-N bis(2-ethyl-4-hydroxyphenyl)methanone Chemical compound CCC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1CC LUBRVTSBOGIRCS-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 150000003667 tyrosine derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A urinoscopic reagent for cancer is prepared from the acidic aqueous solutions of Hg+, Hg2+ and Se. A standard colour board is also disclosed, which is used as colour reference of deposit generated by precipitin reaction of urine sample of the person to be tested. Its advantages are high correctness up to 83%, non-wound test, and easy operation.
Description
The present invention relates to the urinalysis reagent that a kind of cancer generaI investigation screening and the state of an illness are followed the trail of, it comprises by Hg
+, Hg
2+And the acid solution of selenium (Se) composition, reach the Standard colour board that is used to judge when using.It belongs to medicine technology field, also belongs to technological field of biochemistry, and its international Patent classificating number is respectively A61, C12.
Zoopery and cohort study show, tumour be for a long time, stage by stage, develop into the clinical diagnosable cancer that goes out from normal cell, generally will through asymptomatic clinical before the cancer phase.Therefore, just need to use quick, easy screening test, apparent health is in the people of clinical preceding cancer phase, make a distinction with those people that may not have cancer.Screening is not diagnosis, to the screening test positive or probable positive person, need further clarify a diagnosis, so that treatment in time, thereby improve cure rate, reduce treatment of cancer difficulty or cancer mortality.
Be that Study of indexes still is in laboratory stage with the biological markers in the screening test, main cause be some marks of finding at present for example oncogene, tumour antigen etc. lack necessary susceptibility and specificity as screening indexes, and complicated operation, degree of specialization require high former thereby can't widespread use.
The existing report of the research of tumor markers in the urine is as the detection of polyamines in the urine, the detection of compounds containing thiol groups, the detection of some amino acid metabolites etc.Leaf answers lovely grade in " clinical trial diagnostics " (1989, the People's Health Publisher, 1594 pages, 405～406 pages) propose, tyrosine metabolic product ethyl-para-hydroxyphenyl ketone acid content may raise in cancer patient's urine, and available millon reagent is measured, but has many defectives that are difficult for overcoming in the practical application, reason is an inorganic salt concentration height in the urine, can make mercury precipitation in the millon reagent and loses effectiveness.
US Patent specification US-5066601 can not directly measure tyrosine derivative in the urine at millon reagent, has proposed a kind of Hg of using
2+At first, prevent the method that it disturbs entire reaction course, be used for the diagnosis of tumour in conjunction with inorganic salts in the urine, but improper because of the configuration proportion of its reagent, cause its effect not good.
European patent 0341803A, Chinese patent CN1096374A (on Dec 14th, 1994 is open) have then proposed some and have improved one's methods, but owing to its proportioning composition still exists some problems to fail to be applied.
How to judge for the shades of colour reaction that occurs in the practical application, all do not provide clear and definite solution in the above-mentioned patent, thereby limited the application of these reagent more.
The purpose of this invention is to provide a kind of for cancer screening with urinalysis reagent and criterion color board, whether it should detect the measured easily from urine may suffer from cancer, also can be used for detecting patient and has or not recurrence, shifts, evaluation result of treatment etc.
Be the technical measures that realize that the object of the invention is taked: utilize Hg
+, Hg
2+Acid solution with Se, measure some metabolin and the compounds containing thiol groups of tyrosine in the urine, the excretion of the latter in urine changes along with the change of illness state that has that it's too late of cancer, and the reagent that reality obtains is taken photos with the situation of urine sample reaction, as the color standards colour table.
In the composition of this urinalysis reagent, Hg
+With the phenylol generation color reaction of above-mentioned metabolin, Hg
2+Remove inorganic salts and equilibrium system internal reaction in the urine, when Se participates in, produce color reaction with compounds containing thiol groups in the urine, wherein: Hg
+, Hg
2+With the ratio of Se be: 1: 0.1-3.0: 0.001-0.05.
Standard colorimetric plate is made: the urine sample reaction of urinalysis reagent that usefulness prepares and healthy people 3-5 name, all kinds of cancer patient 10-20 names of having made a definite diagnosis, observation post produces precipitation, the tangible sample of precipitation capacity of all kinds of selections and color characteristic thereof is clapped and is made photo or be depicted as colour table, is called the criterion color board.
Using method of the present invention: get urine 3ml, drip reagent 0.5ml of the present invention, have precipitation to generate immediately, vibration was placed after 2 minutes, with the contrast of criterion colour table among the present invention, it is negative to be shallower than No. 1, Standard colour board color, and it is positive to be deeper than No. 2, Standard colour board color.Be the jaundice interference 8-9 number.
Compared with the prior art, effect of the present invention shows following several aspect:
1. utilize this reagent to be used for cancer generaI investigation screening, reach the cancer state of an illness, result of treatment monitoring, simple and easy to do, strong operability detects no wound, no pain.
2. use all kinds of cancer patients that this reagent newly was admitted to hospital, do not do any treatment to 112 examples and detect, check out that 93 examples are positive, testing result and last pathological diagnosis and other imageology diagnosis contrast, accuracy rate on average can be 83%.
3. use this reagent to 195 just the workman generally investigate, 2 examples are weak positive, 2 routine strong positives, positive rate are 2.05%.Wherein 2 routine strong positives are finally made a definite diagnosis and are suffered from early-stage cancer (a routine cancer of the stomach, a routine breast cancer).
4. use this reagent 50 routine healthy blood donors are detected, 1 example is positive, positive rate 2.0%.
5. can calculate according to The above results:
Susceptibility=positive detects number/tested cancer patient sum=83%;
Specificity=feminine gender detects number/tested crowd's sum=97.9%;
Positive predictive value=true positives number/positive detects sum=82.6%;
Negative predictive value=true negative number/feminine gender detects sum=92.7%.
Description of drawings:
Fig. 1 is the Standard colour board of cancer inspection.
No. 1 expression of color is negative among the figure; Color 2-7 number expression is positive; Color 8-9 represents the jaundice interference.
Embodiment:
The preparation of A liquid:
With 15 gram HgSO
4Join 100ml 6N H
2SO
4In, stirring and dissolving, solution is water white transparency liquid.
The preparation of B liquid:
With 80 gram Hg
2(NO
3)
22H
2O adds the dense HNO of 100ml
3In, be green transparent liquid after the dissolving.
The preparation of C liquid:
10 gram metallic seleniums are dissolved in 20ml 6N HNO
3In, not heat, placement is spent the night, and is light yellow transparency liquid.
With A, B, C liquid by volume: mix at 1: 3: 0.01 and the urinalysis reagent of colourless transparent liquid.
Claims (3)
1. one kind is used for cancer wrine examination reagent and the criterion colour table that cancer is generally investigated screening and state of an illness tracking, and it is characterized in that: it comprises by Hg
+, Hg
2+And the Standard colour board that the cancer wrine examination reagent formed according to a certain ratio of the acidic aqueous solution of Se and detected person's urine sample generation precipitation reaction produce the sediment color constitutes;
2. by right 1 described reagent and colour table, it is characterized in that: Hg in the reagent of the present invention
+, Hg
2+With the ratio of Se be 1: 〉=0.1 to 3.0: 〉=0.001 to 0.05;
3. by described reagent of claim 1 and Standard colour board, it is characterized in that: it is the colour table that is produced the sediment change color with cancer wrine examination reagent and all kinds of measured's urine sample generation precipitation reaction that standard colorimetric plate is made, according to measured result select representational sample take pictures or draw after cut out and get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96105436 CN1151525A (en) | 1996-05-07 | 1996-05-07 | Cancer uroscopy reagent and determining standard colour plate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96105436 CN1151525A (en) | 1996-05-07 | 1996-05-07 | Cancer uroscopy reagent and determining standard colour plate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1151525A true CN1151525A (en) | 1997-06-11 |
Family
ID=5118895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 96105436 Pending CN1151525A (en) | 1996-05-07 | 1996-05-07 | Cancer uroscopy reagent and determining standard colour plate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1151525A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008148308A1 (en) * | 2007-06-05 | 2008-12-11 | Yongjian Pi | Urinoscopy reagent for detecting breast malignant disease and its application |
| CN105572110A (en) * | 2014-11-04 | 2016-05-11 | 三星电子株式会社 | A method of and an apparatus for measuring biometric information |
| CN108760735A (en) * | 2018-08-20 | 2018-11-06 | 青岛浦利医疗技术有限公司 | The batch processing device and system of automatic detection color changing reagent |
-
1996
- 1996-05-07 CN CN 96105436 patent/CN1151525A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008148308A1 (en) * | 2007-06-05 | 2008-12-11 | Yongjian Pi | Urinoscopy reagent for detecting breast malignant disease and its application |
| CN105572110A (en) * | 2014-11-04 | 2016-05-11 | 三星电子株式会社 | A method of and an apparatus for measuring biometric information |
| US10055837B2 (en) | 2014-11-04 | 2018-08-21 | Samsung Electronics Co., Ltd. | Method of and apparatus for measuring biometric information |
| CN105572110B (en) * | 2014-11-04 | 2019-03-26 | 三星电子株式会社 | Method and apparatus for measuring biometric information |
| CN108760735A (en) * | 2018-08-20 | 2018-11-06 | 青岛浦利医疗技术有限公司 | The batch processing device and system of automatic detection color changing reagent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107884396A (en) | A kind of online sensing analytical method of ascorbic acid concentrations based on light microscope and auxiliary developer | |
| WO2019023764A1 (en) | Device for detecting the adam10 biomarker for the diagnosis of alzheimer's disease, method for the application of said device, use of said device for the diagnosis of alzheimer's disease, and elisa application method for the diagnosis of alzheimer's disease | |
| CN104390918A (en) | Noninvasive detection system and method of diabetes and complications of diabetes | |
| Westbye et al. | Analysis of free, unbound thyroid hormones by liquid chromatography‐tandem mass spectrometry: A mini‐review of the medical rationale and analytical methods | |
| CN106913348A (en) | A kind of pre-dilution vacuum test tube and measurement platelet count purpose method | |
| JP4200187B2 (en) | How to determine kidney clearance | |
| CN1151525A (en) | Cancer uroscopy reagent and determining standard colour plate | |
| BRPI0901542A2 (en) | microtube reader device for the analysis of blood samples | |
| EP2623979A1 (en) | Immunochromatographic inspection method and device | |
| García et al. | Fluorescent determination of chloride in nanoliter samples | |
| CN105606418A (en) | Integral kit detecting glycosylated hemoglobin and detection method thereof | |
| Brunette et al. | Fluorometric method for the determination of magnesium in renal tubular fluid | |
| CN106872379B (en) | A kind of urinary fractions analyzer | |
| CN102175674A (en) | Method for detecting trace of albumin in urine | |
| US3761227A (en) | Method for detection of opium derivatives in urine | |
| EP1828781A1 (en) | Assay for generation of a lipid profile using fluorescence measurement | |
| CN107091934B (en) | A kind of direct bilirubin detecting kit and configuration method and its utilization | |
| Thysell | A COMPARISON BETWEEN ALBUSTIX, HEMA‐COMBISTIX, LABSTIX, THE SULPHOSALICYLIC‐ACID TEST, HELLER'S NITRIC‐ACID TEST, AND A BIURET METHOD: Diagnosis of Proteinuria | |
| RU2098819C1 (en) | Method for diagnosing patient digestive tract pathology | |
| Eichhorn et al. | Fluorometric method for quantitatively estimating urinary dihydroxyphenylethylamine (dopamine), dihydroxyphenylalanine (dopa), and dihydroxyphenylacetic acid (dopac) | |
| RU2279681C2 (en) | Method for quick-test detection of urinary calcium content | |
| RU2313091C2 (en) | Method for determination of blood cells dynamics precipitation | |
| RU2760837C1 (en) | Method for determining time remoteness of injury that caused posttraumatic hemarthrosis | |
| CN112649609A (en) | Urotrypsinogen-2 detection reagent tablet and application thereof in pancreatic disease diagnosis | |
| RU2229131C1 (en) | Method for diagnosing sensorineural deafness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |